Vault-13

ARCH Venture Management, LLC

CHICAGO, IL · CIK 1274403 · 13F filing filed 2026-08-14

Exempt reporting adviser since 2012 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Chicago, IL (main office)United States United States
Mercer Island, WAUnited States United States1

US visa salary filings

Job titleFilingsMedianRange
PrincipalChicago, IL 1 $157,394 $157,394 – $500,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: ARCH Venture Management, LLC.

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$1.1bn reported value +62.5% vs Q1 2026
12positions
99.3%in top 10
3 new 0 added 1 reduced 1 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 PARABILIS MEDICINES INC COM PBLS PBLS 6,412,780 $175.5m15.95% 15.95% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 6.4m
2 BEAM THERAPEUTICS INC COM BEAM BEAM 4,540,132 $155.8m14.16% 14.16% UnchangedShares held: Q3 2025 4.5m, Q4 2025 4.5m, Q1 2026 4.5m, Q2 2026 4.5m
3 RAPPORT THERAPEUTICS INC COM RAPP RAPP 3,728,738 $155.4m14.12% 14.12% UnchangedShares held: Q3 2025 3.7m, Q4 2025 3.7m, Q1 2026 3.7m, Q2 2026 3.7m
4 SEAPORT THERAPEUTICS INC COMMON STOCK SPTX SPTX 6,294,951 $136.6m12.42% 12.42% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 6.3m
5 ERASCA INC COM ERAS ERAS 7,091,557 $129.9m11.81% 11.81% UnchangedShares held: Q3 2025 11.1m, Q4 2025 11.1m, Q1 2026 7.1m, Q2 2026 7.1m
6 VIR BIOTECHNOLOGY INC COM VIR VIR 12,694,163 $129.4m11.76% 11.76% ReducedShares held: Q3 2025 12.9m, Q4 2025 12.9m, Q1 2026 12.9m, Q2 2026 12.7m -222.5k -222,500 -1.7%
7 MAZE THERAPEUTICS INC COM MAZE MAZE 4,120,053 $123.0m11.18% 11.18% UnchangedShares held: Q3 2025 4.1m, Q4 2025 4.1m, Q1 2026 4.1m, Q2 2026 4.1m
8 LYELL IMMUNOPHARMA INC COM NEW LYEL LYEL 3,247,162 $45.5m4.14% 4.14% UnchangedShares held: Q3 2025 2.8m, Q4 2025 2.8m, Q1 2026 3.2m, Q2 2026 3.2m
9 GENERATE BIOMEDICINES INC COM SHS GENB GENB 1,944,426 $32.8m2.98% 2.98% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 1.9m, Q2 2026 1.9m
10 10X GENOMICS INC CL A COM TXG TXG 217,834 $8.4m0.76% 0.76% UnchangedShares held: Q3 2025 0, Q4 2025 737.5k, Q1 2026 217.8k, Q2 2026 217.8k
11 BOUNDLESS BIO INC COM BOLD BOLD 2,694,095 $6.7m0.61% 0.61% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 2.7m
12 GOSSAMER BIO INC COM GOSS GOSS 8,055,916 $1.3m0.12% 0.12% UnchangedShares held: Q3 2025 8.1m, Q4 2025 8.1m, Q1 2026 8.1m, Q2 2026 8.1m

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
Q32 BIO INC QTTB QTTB 320,482 $2.1m320.5k shares